MAIA Biotechnology, Inc.
MAIA- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001878313
In the last 90 days, MAIA Biotechnology, Inc. insiders filed 5 open-market purchases and 0 sales; 36 institutions reported holding it in 13F filings for Q2 2026, worth $19.4M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding MAIA Biotechnology, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 0 | 9 | +9 |
| Shares | 0 | 231.3K | +231.3K |
| Value | $0 | $763.0K | +$763.0K |
New holders (9)
Institutions that held MAIA Biotechnology, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Lynwood Capital Management Inc. | 199,785 | $659.0K | 0.72% |
| Millennium Management LLC | 11,811 | $39.0K | 0.00% |
| Jane Street Group, LLC | 10,210 | $34.0K | 0.00% |
| UBS Group AG | 4,588 | $15.0K | 0.00% |
| BlackRock Inc. | 3,572 | $12.0K | 0.00% |
| Optimum Investment Advisors | 1,000 | $3.00K | 0.00% |
| Tower Research Capital LLC (TRC) | 311 | $1.00K | 0.00% |
| Wells Fargo & Company | 14 | $0 | 0.00% |
| Royal Bank of Canada | 22 | $0 | 0.00% |
Sold out (0)
Institutions that held MAIA Biotechnology, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
None.